Question 1

What is DNL593?

Accepted Answer

DNL593 is a Other.

Question 2

How often does DNL593 appear in global news?

Accepted Answer

Tracked across 1 news events drawn from 7 articles.

Question 3

When was DNL593 first tracked by Ergen?

Accepted Answer

First tracked on Apr 03, 2026.

Question 4

When was DNL593 last mentioned in news?

Accepted Answer

Last active on Apr 03, 2026.

Question 5

What is DNL593's current news sentiment?

Accepted Answer

Aggregate sentiment score: 20 on a -100 to +100 scale (negative = critical coverage, positive = favorable coverage).

Question 6

How prominent is DNL593 in global news coverage?

Accepted Answer

Attention score of 4, derived from article volume and coverage intensity across 1 events.

Question 7

What is the most recent event involving DNL593?

Accepted Answer

Takeda Terminates DNL593 Collaboration with Denali (Apr 03, 2026, 7 articles).

Question 8

How did the "Takeda Terminates DNL593 Collaboration with Denali" event impact DNL593?

Accepted Answer

DNL593 is an investigational progranulin replacement therapy for frontotemporal dementia-granulin (FTD-GRN), which Denali Therapeutics will now develop independently.

Question 9

How is this data collected?

Accepted Answer

Ergen aggregates thousands of global news sources and extracts structured events, entities, and relationships with sentiment and attention metrics. Pages are daily static snapshots from the platform's live database.